Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients
Brief Summary: This randomized phase III trial studies octreotide acetate and recombinant interferon alfa-2b to see how well it works compared to octreotide acetate and bevacizumab in treating patients with high-risk neuroendocrine tumors that have spread to other places in the body (metastatic) or spread from where it started to nearby tissue or lymph nodes (locally advanced). Octreotide acetate and recombinant interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving octreotide acetate together with recombinant interferon alfa-2b is more effective than giving octreotide acetate together with bevacizumab in treating patients with neuroendocrine tumor.


Options:
A: Arm Label: Lanreotide Autogel 120mg & Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Lanreotide Autogel 120 mg, Drug: Temozolomide (TMZ) | Intervention Type: DRUG; Name: Lanreotide Autogel 120 mg; Assigned to Arm(s): Lanreotide Autogel 120mg & Temozolomide | Intervention Type: DRUG; Name: Temozolomide (TMZ); Assigned to Arm(s): Lanreotide Autogel 120mg & Temozolomide
B: Arm Label: Surufatinib; Type: EXPERIMENTAL; Interventions: Drug: Surufatinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Surufatinib; Assigned to Arm(s): Surufatinib | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Arm I (octreotide acetate and bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Drug: Octreotide Acetate | Arm Label: Arm II (octreotide acetate and recombinant interferon alfa-2b); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Drug: Octreotide Acetate, Biological: Recombinant Interferon Alfa-2b | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm I (octreotide acetate and bevacizumab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (octreotide acetate and bevacizumab), Arm II (octreotide acetate and recombinant interferon alfa-2b) | Intervention Type: DRUG; Name: Octreotide Acetate; Assigned to Arm(s): Arm I (octreotide acetate and bevacizumab), Arm II (octreotide acetate and recombinant interferon alfa-2b) | Intervention Type: BIOLOGICAL; Name: Recombinant Interferon Alfa-2b; Assigned to Arm(s): Arm II (octreotide acetate and recombinant interferon alfa-2b)
D: Arm Label: Octreotide+ Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Octreotide, Drug: Everolimus | Arm Label: Octreotide+ Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Octreotide, Drug: Placebo | Intervention Type: DRUG; Name: Octreotide; Assigned to Arm(s): Octreotide+ Everolimus, Octreotide+ Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Octreotide+ Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Octreotide+ Everolimus

Answer: C